NCT06554717View on ClinicalTrials.gov

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

June 30, 2028

Conditions
HIV-1-infectionFrailtyImpaired Physical FunctionAbdominal ObesityAging
Interventions
DRUG

Tesamorelin

Tesamorelin WR 1.28 mg given subcutaneously daily

DRUG

Placebo

Identical placebo injection given subcutaneously daily

BEHAVIORAL

Exercise

Home-based semi-supervised exercise program

Trial Locations (2)

80045

RECRUITING

University of Colorado - Anschutz Medical Campus, Aurora

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

University of Colorado, Denver

OTHER

lead

Massachusetts General Hospital

OTHER

NCT06554717 - Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV | Biotech Hunter | Biotech Hunter